Compliance and persistence in patients with primary open-angle glaucoma through the doctor opinions

PURPOSE: Determination of key factors of non-compliance for treatment and duration of recommendations accomplishment in accordance with doctor’s instructions and associated with time from therapy start to its discontinuation (persistence) in patients with glaucoma by assessment of personal opinion of ophthalmologists with different amount of experience.

METHODS: 509 queries of medical professionals (631 doctors) from Russia and other 6 countries were included into the study. All doctors’ queries were grouped according to the duration of their work experience, place of work — depending on medical care type (ambulatory or inpatient) and by hospital propriety type (state or private). Data collection method: online survey. The significance of the 32 selected compliance factors was assessed by the ball system from 10 (maximum significant factor) to 1 (minimally significant factor). Analysis program Statistica 8.0 (StatSoft Inc., USA).

RESULTS: Data analysis allowed determining medium terms for continued application of recommended therapy depending on patients group. Persistency of low-compliant patients was considered a period of continued following of recommendations from 15 up to 27.5 days per year, high-compliant — 180-300 days per year. Doctors’ opinion depended on time in professional and place of work. Study results allowed recognizing percent’s of “low-compliant”, “mediumcompliant” and “high-compliant” patients. Following patients compliance factors were assessed as well: factors directly associated with treatment, factors, associated with patient’s condition, factors of behavioral compliance and social compliance. Moreover, trial results displayed difference in opinion of medical specialists depending on the duration of their work experience, place of work and clinic type.

CONCLUSION: Study groups divided by the amount of healthcare experience showed no difference in patients compliance apprehension. Percentage of low-compliant patients was 20 [10; 30] %; medium-compliant — 30 [20; 45] and high-compliant — 50 [30; 60]% in all groups. A longer duration of healthcare experience corresponded with higher persistence requirements. Low-compliant patients followed recommendations for up to 20 days per year [7; 60]; medium-compliant — for 90 [20; 200] and lowcompliant — 200 [40; 350]. Primary factors for non-compliancy in all groups were defined as follows: absence of motivation; complicated instillation regimen influencing daily activities; absence of contact with attending physician; low information level concerning condition; age; side effects; medication price; laziness; family history of glaucoma. Factors of behavioral compliance were considered the most important in all groups — 75%.

1. Kazanova S.Y. Analysis of treatment adherence in chronic disease patients. National Journal glaucoma. 2018; 17(3):97-110. (In Russ.).

2. Kozina E.V. Psychological characteristic of patients with primary open-angle glaucoma. Vestnik oftal’mologii. 2002; 3:38-40. (In Russ.).

3. Kharkovskii A.O. Kak zastavit' patsienta lechit'sya? [How to get a patient to be treated?] Prague: Linksolutions; 2012. 76 p.

4. Alexeyev V.N., Malevanova O.A. Study of the quality of life of patients with primary open-angle glaucoma. RMJ Clinical Ophthalmology. 2003; 3:113-115. (In Russ.).

5. Schulz M., Krueger K., Schuessel K., Friedland K., Laufs U., Mueller W.E., Ude M. Medication adherence and persistence according to different antihypertensive drug classes: A retrospective cohort study of 255,500 patients. Int J Cardiol. 2016; 220:668-676.

6. Robin A., Grover D.S. Compliance and adherence in glaucoma management. Indian J Ophthalmol. 2011; 59: Suppl:S93–96.

7. Rees G., Chong X., Cheung C.Y., Aung T., Friedman D.S., Crowston J.G. et al. Beliefs and adherence to glaucoma treatment: a comparison of patients from diverse cultures. J Glaucoma. 2014; 23(5):293–298.

8. Mohindroo C., Ichhpujani P., Kumar S. How ‘Drug Aware’ are our Glaucoma Patients? J Curr Glaucoma Pract. 2015; 9(2):33–37.

9. Boland M.V., Chang D.S., Frazier T., Plyler R., Friedman D.S. Electronic monitoring to assess adherence with once-daily glaucoma medications and risk factors for nonadherence: the automated dosing reminder study. JAMA Ophthalmol. 2014; 132(7): 838–844.

10. Dietlein T.S., Rosentreter A., Lappas A. Complexities of medical glaucoma therapy — the elderly patient in focus. Klin Monbl Augenheilkd. 2016; 233(2):138–142.

11. Friedman D.S., Quigley H.A., Gelb L., Tan J., Margolis J., Shah S.N. et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci. 2007; 48(11):5052–5057.

12. Stryker J.E., Beck A.D., Primo S.A., Echt K.V., Bundy L., Pretorius G.C. et al. An exploratory study of factors influencing glaucoma treatment adherence. J Glaucoma. 2010; 19(1):66–72.

13. Kholdebarin R., Campbell R.J., Jin Y.P., Buys Y.M. Multicenter study of compliance and drop administration in glaucoma. Can J Ophthalmol. 2008; 43(4): 454–461.

14. Lanzl I., Kaercher T. Preservative-containing eye drops and adherence in ophthalmological practice. Ophthalmologe. 2012; 109(11): 1087–1092.

15. Mansberger S.L. Are you compliant with addressing glaucoma adherence? Am J Ophthalmol. 2010; 149(1):1-3.

16. Gabdrakhmanova A.F., Kurbanov S.A., Kunafin E.R. Some aspects of complex treatment of open-angle glaucoma. Medicine Bashkortostan Vestnik. 2014; 2:42-45. (In Russ.).

17. Illarionova A.R. Study of quality of life in patients with glaucoma. RMJ Clinical Ophthalmology. 2003; 3:134-137. (In Russ.).

18. Alexeyev V.N., Malevany O.A. On the quality of dispensary surveillance in the primary open-angle glaucoma RMJ Clinical Ophthalmology. 2003; 3:119-122. (In Russ.).

19. Alexeyev V.N., Malevannaya O.A., Samih El Hazh N. Reasons for low commitment to the treatment of patients with primary open-angle glaucoma. Oftalmologičeskie vedomosti. 2010; 4:37-39. (In Russ.).

20. Glaukoma. Nacional`noe rukovodstvo. [Glaucoma. National Guide]. Ed. by E.A. Egorov. Moscow: GEOTAR Media; 2013. 824 p. (In Russ.).

21. Egorov E.A., Lovpache J.N., Kharkiv A.O. "Compliance" — what is behind this term? RMJ Clinical Ophthalmology. 2008; 3:84-86. (In Russ.).

22. Liebman E.S., Halperin M.R., Grishin E.E., Senkevich N.Y. Approaches to assessing the quality of life of ophthalmic patients. RMJ Clinical Ophthalmology. 2002; 3:119-121. (In Russ.).

23. Alexeyev V.N., Malevanova O.A. Study of the quality of life of patients with primary open-angle glaucoma. RMJ Clinical Ophthalmology. 2003; 3:113-115. (In Russ.).

24. Alexeyev V.N., Malevany O.A., Samih El Hazh N. et al. Analysis of the main causes of the progression of primary open-angle glaucoma. Oftalmologičeskie vedomosti. 2011; 2:31-34. (In Russ.).

25. Alexeyev V.N., Yegorov E.A., Malevannaya O.A. et al. Analysis of the main causes of the progression of primary open-angle glaucoma. RMJ Clinical Ophthalmology. 2014; 4:218-223. (In Russ.).

26. Dolgova I.G., Malishevskaya T.N., Lazareva A.S. Compliance and "Patient School": solving a common problem. Glaukoma. 2009; 3:35-41. (In Russ.).

27. Kuroedov A.V. Compliance in glaucoma therapy. Moscow: GEOTARMedia; 2017. Electronic module. Access by link http://www.rosmedlib.ru/book/07-MOD-2330.html

28. Kuroedov A.V., Brezhnev A.Yu. Duration of antihypertensive action of antiglaucoma drugs. RMJ Clinical Ophthalmology. 2016; 17(4): 214-219. (In Russ.).

29. Onishchenko A.L., Kolbasko A.V., Safronova M.A., Isakov I.N. Causes of CVD resistance to hypotensive therapy in patients with glaucoma Vestnik oftal’mologii. 2016; 3:49-51. (In Russ.).

30. Frantzuzova L.V., Galeyev A.S., Gabdrakhmanov L.M., Karlova E.V. Features of the psycho-emotional state of patients with primary openangle glaucoma. Vestnik Orenburgskogo gosudarstvennogo universiteta. 2015; 12:266-269. (In Russ.).

31. Kharkovskii A.O. Kak zastavit' patsienta lechit'sya? [How to get a patient to be treated?] Prague, Linksolutions; 2012. 76 p.

32. Kunin V.D., Redid A.A. Dynamics of the glaucoma process in patients who observed and did not observe the regime of dispensary observation and treatment. Tochka zreniya. Vostok - Zapad. 2017; 4:14-17. (In Russ.).

33. Malevaned O.A., Samih El Hazh N., Salah M.H. The idea of "compliance" in modern medicine and ophthalmology. Preventive and clinical medicine. 2011; 3:331-335. (In Russ.).

34. Malishevskaya T.N., Dolgov I.G., Shatsky S.V. et al. Differential approach to the treatment of patients with primary open-angle glaucoma. Natsional'nyy zhurnal glaukoma. 2017; 3:12-17. (In Russ.).

35. Petrov S.Y., Lovpache Dzh.N. Principles of commitment to treatment among patients with glaucoma according to the 4th edition of the European Glaucoma Guide (analytical commentary). RMJ Clinical Ophthalmology. 2015; 3:152-154. (In Russ.).

36. Danilov D.S. Compliance mechanisms and modern approaches to optimizing it. Russian medical news. 2008; 3:11–24. (In Russ.).

37. Casanova S.Y., Strakhov V.V., Yartsev A.V. Price of glaucoma treatment through the eyes of patients. Oftalmologičeskie vedomosti. 2013; 4:15-20. (In Russ.).

38. Casanova S.Y., Strakhov V.V. Analysis of the rate of progression of the glaucoma process with various non-compliance options of treatment compliance. Natsional'nyy zhurnal glaukoma. 2016; 2:74-83. (In Russ.).

39. Batyrshina L.F., Valiullina S.N., Ishakov E.R., Galimov R.N. Vision Treatment Strategy for patients with somatic diseases depending on psychological status. Vestnik oftal’mologii. 2008; 3:41-43. (In Russ.).